Labcorp Unveils First FDA-Approved PTEN Diagnostic to Target Prostate Cancer Treatment

Labcorp Introduces FDA-Approved PTEN Companion Diagnostic for Prostate Cancer

In a significant advancement for prostate cancer management, Labcorp has announced the nationwide launch of the VENTANA® PTEN (SP218) RxDx Assay. This groundbreaking diagnostic test, recently approved by the U.S. Food and Drug Administration (FDA), is designed to detect the loss of PTEN protein in prostate adenocarcinoma tumors, providing crucial information that could guide treatment decisions for many patients.

Understanding the Need

Every year, over 330,000 new cases of prostate cancer are diagnosed in the United States, making it the most common cancer among men, excluding skin cancers. PTEN, a vital tumor suppressor protein, plays an essential role in cell regulation and growth. The absence of PTEN has been correlated with aggressive cancer progression and diminished effectiveness of standard treatments. Unfortunately, until the introduction of this diagnostic tool, there were no specific treatment pathways targeting PTEN loss in prostate cancer management.

The Role of the VENTANA PTEN (SP218) RxDx Assay

The newly available VENTANA PTEN (SP218) RxDx Assay enables physicians to assess PTEN deficiency in prostate cancer tissue samples. This valuable biomarker information can dramatically inform personalized treatment plans, potentially connecting patients to more effective therapies.

Dr. Shakti Ramkissoon, Vice President and Medical Lead for Oncology at Labcorp, emphasized the importance of biomarker testing in enhancing precision oncology. He remarked, "The launch of the VENTANA PTEN (SP218) RxDx Assay highlights Labcorp’s commitment to ensuring patients have access to state-of-the-art companion diagnostics that enable timely, informed treatment strategies."

The PTEN diagnostic sits within a broader context, complementing Labcorp's array of genomic, molecular, and companion testing services designed for precision oncology. This multi-faceted approach allows healthcare providers to have comprehensive insights, ensuring that the right patient receives the right treatment based on their unique cancer profile.

Advancing Access to Innovative Diagnostics

Labcorp has actively participated in Roche’s early access program to ensure that laboratories were prepared to launch the assay immediately post-approval. This initiative reflects the organization’s ongoing dedication to facilitating timely access to novel therapies and the necessary diagnostics for patient eligibility.

Now accessible through Labcorp’s extensive network of laboratories, the VENTANA PTEN (SP218) RxDx Assay is an integral part of a complete suite of oncology testing services. As one of the leading providers of oncology testing in the nation, Labcorp is committed to democratizing access to companion diagnostics, ensuring that patients receive tailored cancer treatments, irrespective of where they are being treated.

Conclusion

With the launch of the VENTANA PTEN (SP218) RxDx Assay, Labcorp is at the forefront of enhancing prostate cancer care. This diagnostic tool not only aids in identifying patient eligibility for groundbreaking therapies like AstraZeneca's TRUQAP® (capivasertib) in combination with other treatments but also embodies a pivotal shift toward more personalized, effective cancer management. As the field of oncology continues to evolve with precision medicine, Labcorp remains dedicated to empowering patients and clinicians with the tools necessary for informed decision-making in cancer therapy. To know more about the assay, interested patients and healthcare professionals can visit Labcorp's official site.